World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
29526
World Ranking
17397
National Ranking
8712

Vered Stearns publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Vered Stearns sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 711 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Vered Stearns D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Vered Stearns sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 79 D-Index — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Vered Stearns is affiliated with Johns Hopkins University in the United States and has a significant body of research in the fields of Medicine, particularly focusing on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology, and Genetics.

Stearns' research primarily addresses topics such as:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • Cancer Immunotherapy and Biomarkers
  • Estrogen and related hormone effects
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Cancer survivorship and care

With a publication record featuring prominent journals, Stearns has frequently published in:

  • Cancer Research
  • Journal of Clinical Oncology
  • ONCOLOGY
  • Breast Cancer Research and Treatment
  • Annals of Oncology

Among recent notable papers authored or coauthored by Stearns are:

  • ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4), 2020, Annals of Oncology
  • Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials, 2022, Journal of Clinical Oncology
  • TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker, 2020, Annals of Oncology
  • Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach, 2020, JCO Oncology Practice
  • Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer, 2020, Frontiers in Physiology

Stearns has collaborated extensively with several researchers, including:

  • Antonio C. Wolff
  • Roisín M. Connolly
  • Karen L. Smith
  • Jennifer Y. Sheng
  • Amanda L. Blackford

Their scholarly contributions span clinical and molecular investigations, especially in breast cancer, exploring treatment efficacy, immunological markers, and cancer subtype-specific management strategies. The data indicates a sustained focus on both clinical outcomes and biomarker development in cancer research.

Best Publications

  • CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

    Yan Jin;Zeruesenay Desta;Vered Stearns;Bryan Ward

  • American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

    Harold J. Burstein;Ann Alexis Prestrud;Jerome Seidenfeld;Holly Anderson

  • Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

    Vered Stearns;Michael D. Johnson;James M. Rae;James M. Rae;Alan Morocho

  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

    Harold J. Burstein;Harold J. Burstein;Sarah Temin;Holly Anderson;Thomas A. Buchholz

  • Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

    Manfred Kaufmann;Gabriel N. Hortobagyi;Aron Goldhirsch;Suzy Scholl

  • Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Olivia Pagani;Meredith M. Regan;Barbara A. Walley;Gini F. Fleming

  • Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

    Ayca Gucalp;Ayca Gucalp;Sara Tolaney;Steven J. Isakoff;James N. Ingle

  • Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized, controlled trial

    Vered Stearns;Katherine L. Beebe;Malini Iyengar;Eric Dube

  • Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

    Hsing Chen Tsai;Huili Li;Leander Van Neste;Yi Cai

  • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

    P. A. Francis;P. A. Francis;O. Pagani;G. F. Fleming;B. A. Walley

  • Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

    Silvana Borges;Zeruesenay Desta;Lang Li;Todd C Skaar

  • Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

    M. Kaufmann;G. Von minckwitz;H. D. Bear;Aman U Buzdar

  • TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

    Steven J. Isakoff;Erica L. Mayer;Lei He;Tiffany A. Traina

  • Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.

    Huili Li;Katherine B. Chiappinelli;Angela A. Guzzetta;Hariharan Easwaran

  • When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer

    Hideko Yamauchi;Vered Stearns;Daniel F. Hayes

  • Detection of cancer DNA in plasma of patients with early-stage breast cancer.

    Julia A. Beaver;Danijela Jelovac;Sasidharan Balukrishna;Rory L. Cochran

  • Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer

    N. Lynn Henry;Faouzi Azzouz;Zereunesay Desta;Lang Li

  • Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood

    Michaela J Higgins;Danijela Jelovac;Evan Barnathan;Brian Blair

  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression

    Harold J. Burstein;Christina Lacchetti;Holly Anderson;Thomas A. Buchholz

  • Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

    Harold J. Burstein;Christina Lacchetti;Holly Anderson;Thomas A. Buchholz

Frequent Co-Authors

Antonio C. Wolff
Antonio C. Wolff Johns Hopkins University
Daniel F. Hayes
Daniel F. Hayes University of Michigan–Ann Arbor
David A. Flockhart
David A. Flockhart Indiana University
Nancy E. Davidson
Nancy E. Davidson University of Washington
Saraswati Sukumar
Saraswati Sukumar Johns Hopkins University School of Medicine
Eric P. Winer
Eric P. Winer Yale University
Edward Gabrielson
Edward Gabrielson Johns Hopkins University School of Medicine
Lisa A. Carey
Lisa A. Carey University of North Carolina at Chapel Hill
Steffi Oesterreich
Steffi Oesterreich University of Pittsburgh
Elizabeth M. Jaffee
Elizabeth M. Jaffee Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always require medical school. There are many related online degree options that can open doors to rewarding healthcare roles. For instance, those interested in pharmaceuticals can consider online pharmacy school programs, which offer flexibility for working professionals.

Another growing field is health informatics. By earning a degree in health informatics, you can help manage patient data, medical records, and ensure compliance with healthcare regulations.

For those who prefer administrative roles, medical billing and coding online courses cost significantly less than traditional programs and lead to essential positions in healthcare administration.

If you're aiming for a more advanced clinical pathway, becoming a nurse practitioner may be ideal. The cheapest np school options online make this career goal more attainable.

Each of these online programs offers a unique entry point into the expanding field of medicine, providing both affordability and flexibility to suit diverse career ambitions.

Best Scientists Citing Vered Stearns

Trending Scientists

Recently Published Articles